China's first domestically developed oral drug for COVID-19 treatment has set its initial price at less than 300 yuan per bottle, as observers said the drug will help ensure more Chinese families access to COVID-19 treatment.
Azvudine, produced by Genuine Biotech Limited, based in Central China's Henan Province, contains 35 tablets per bottle with 1 milligram per tablet. The price per bottle has been set at less than 300 yuan, reported Henan Daily on Sunday.
Observers said the approval of Azvudine, sold at less than 1,000 yuan per course, will ensure more Chinese families can have access to COVID-19 treatment as other approved drugs have caused controversy on Chinese social media with some netizens concerned that the prices might be too expensive for many families to afford.
China approved Pfizer's COVID-19 pill Paxlovid and the domestic neutralizing antibody therapy BRII-196/BRII-198 for COVID-19 treatment. Paxlvoid is sold at about 2,400 yuan per course and the BRII-196/BRII-198 therapy costs 10,000 yuan for one course of treatment.
The drug was officially put into production on Tuesday. The Chinese National Medical Products Administration granted conditional approval to Azvudine for COVID-19 treatment on July 25.
